20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. This is a 75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $353.375 thousand which missed the analyst consensus estimate of $779.000 thousand by 54.64 percent. This is a 36.19 percent decrease over sales of $553.820 thousand the same period last year.